116 related articles for article (PubMed ID: 38569540)
1. Intense 18 F-FAPI Uptake in Small Recurrent Lesions of Combined Hepatocellular-Cholangiocarcinoma Negative on 18 F-FDG PET/CT.
Liang J; Zhang J; Song J; Zhang R; Zhang L
Clin Nucl Med; 2024 Jul; 49(7):e351-e353. PubMed ID: 38569540
[TBL] [Abstract][Full Text] [Related]
2. Prognostic value of
Lim CH; Moon SH; Cho YS; Choi JY; Lee KH; Hyun SH
Eur J Nucl Med Mol Imaging; 2019 Jul; 46(8):1705-1712. PubMed ID: 31049603
[TBL] [Abstract][Full Text] [Related]
3. 68 Ga-FAPI-04 PET/CT for the Evaluation of Cholangiocarcinoma : Comparison With 18 F-FDG PET/CT and Abdominal 68 Ga-FAPI-04 PET/MR.
Zhang Z; Cheng C; Jiang H; Pan G; Yu Y; Jin G; Zuo C
Clin Nucl Med; 2024 May; 49(5):409-418. PubMed ID: 38465929
[TBL] [Abstract][Full Text] [Related]
4. Comparison of PET imaging of activated fibroblasts and
Shi X; Xing H; Yang X; Li F; Yao S; Congwei J; Zhao H; Hacker M; Huo L; Li X
Eur J Nucl Med Mol Imaging; 2021 May; 48(5):1593-1603. PubMed ID: 33097975
[TBL] [Abstract][Full Text] [Related]
5. Elevated 18 F-AIF-FAPI-04 Uptake in Hepatic Hemangioma.
Sun Y; Cai X; Wang Z; Sun Y; Cheng J
Clin Nucl Med; 2024 Jan; 49(1):e25-e27. PubMed ID: 38015630
[TBL] [Abstract][Full Text] [Related]
6. Superior Tumor Detection for
Pabst KM; Trajkovic-Arsic M; Cheung PFY; Ballke S; Steiger K; Bartel T; Schaarschmidt BM; Milosevic A; Seifert R; Nader M; Kessler L; Siveke JT; Lueckerath K; Kasper S; Herrmann K; Hirmas N; Schmidt HH; Hamacher R; Fendler WP
J Nucl Med; 2023 Jul; 64(7):1049-1055. PubMed ID: 37024301
[TBL] [Abstract][Full Text] [Related]
7. Head-to-head comparison of
Zhang J; Jiang S; Li M; Xue H; Zhong X; Li S; Peng H; Liang J; Liu Z; Rao S; Chen H; Cao Z; Gong Y; Chen G; Zhang R; Zhang L
Cancer Imaging; 2023 Oct; 23(1):106. PubMed ID: 37899452
[TBL] [Abstract][Full Text] [Related]
8. [
Zhang J; He Q; Jiang S; Li M; Xue H; Zhang D; Li S; Peng H; Liang J; Liu Z; Rao S; Wang J; Zhang R; Zhang L
Eur J Nucl Med Mol Imaging; 2023 Feb; 50(3):937-950. PubMed ID: 36346437
[TBL] [Abstract][Full Text] [Related]
9. [F-18]fluorodeoxyglucose positron emission tomography and positron emission tomography: computed tomography in recurrent and metastatic cholangiocarcinoma.
Jadvar H; Henderson RW; Conti PS
J Comput Assist Tomogr; 2007; 31(2):223-8. PubMed ID: 17414758
[TBL] [Abstract][Full Text] [Related]
10. Dynamic
Wang J; Shao Y; Liu B; Wang X; Geist BK; Li X; Li F; Zhao H; Hacker M; Ding H; Zhang H; Huo L
BMC Med Imaging; 2021 May; 21(1):90. PubMed ID: 34034664
[TBL] [Abstract][Full Text] [Related]
11. Comparison of 68Ga-FAPI and 18F-FDG PET/CT in a Patient With Cholangiocellular Carcinoma: A Case Report.
Pang Y; Hao B; Shang Q; Sun L; Chen H
Clin Nucl Med; 2020 Jul; 45(7):566-567. PubMed ID: 32371618
[TBL] [Abstract][Full Text] [Related]
12. Comparisons of Quantitative Parameters of Ga-68-Labelled Fibroblast Activating Protein Inhibitor (FAPI) PET/CT and [
Siripongsatian D; Promteangtrong C; Kunawudhi A; Kiatkittikul P; Boonkawin N; Chinnanthachai C; Jantarato A; Chotipanich C
Mol Imaging Biol; 2022 Oct; 24(5):818-829. PubMed ID: 35486293
[TBL] [Abstract][Full Text] [Related]
13. Role of 68 Ga-FAPI PET/CT in Assessing Hepatobiliary Malignancies : A Prospective Pilot Study.
Rajaraman V; Meenakshi LA; Selvaraj AJ; Pottakkat B; Halanaik D
Clin Nucl Med; 2023 Jun; 48(6):e281-e288. PubMed ID: 37019124
[TBL] [Abstract][Full Text] [Related]
14. Three Primary Carcinomas on 18F-FDG PET/CT: Intrahepatic Cholangiocarcinoma, Papillary Renal Cell Carcinoma, and Clear Cell Renal Cell Carcinoma.
Wu D; Hu Y; Wei Q; Tian C; Bian Y
Clin Nucl Med; 2018 Jun; 43(6):428-430. PubMed ID: 29561526
[TBL] [Abstract][Full Text] [Related]
15. Combined hepatocellular carcinoma and cholangiocarcinoma with high F-18 fluorodeoxyglucose positron emission tomographic uptake.
Shiomi S; Sasaki N; Kawashima D; Jomura H; Fukuda T; Kuroki T; Koyama K; Kawabe J; Ochi H
Clin Nucl Med; 1999 May; 24(5):370-1. PubMed ID: 10232488
[No Abstract] [Full Text] [Related]
16. Role of 18F-FDG PET/CT Imaging in Intrahepatic Cholangiocarcinoma.
Jiang L; Tan H; Panje CM; Yu H; Xiu Y; Shi H
Clin Nucl Med; 2016 Jan; 41(1):1-7. PubMed ID: 26402131
[TBL] [Abstract][Full Text] [Related]
17. Value of ¹⁸F-FDG-PET/CT in the detection of recurrent hepatocellular carcinoma after hepatectomy or radiofrequency ablation: a comparative study with contrast-enhanced ultrasound.
Wang XY; Chen D; Zhang XS; Chen ZF; Hu AB
J Dig Dis; 2013 Aug; 14(8):433-8. PubMed ID: 23615075
[TBL] [Abstract][Full Text] [Related]
18. Dual-tracer PET/CT imaging in evaluation of metastatic hepatocellular carcinoma.
Ho CL; Chen S; Yeung DW; Cheng TK
J Nucl Med; 2007 Jun; 48(6):902-9. PubMed ID: 17504862
[TBL] [Abstract][Full Text] [Related]
19. Clinical prospective study of Gallium 68 (
Jinghua L; Kui X; Deliang G; Bo L; Qian Z; Haitao W; Yaqun J; Dongde W; Xigang X; Ping J; Shengli T; Zhiyong Y; Yueming H; Zhonglin Z; Yong H; Yufeng Y
Eur J Nucl Med Mol Imaging; 2023 Jun; 50(7):2152-2166. PubMed ID: 36809426
[TBL] [Abstract][Full Text] [Related]
20. FDG PET/CT in Pancreatic and Hepatobiliary Carcinomas: Value to Patient Management and Patient Outcomes.
Parikh U; Marcus C; Sarangi R; Taghipour M; Subramaniam RM
PET Clin; 2015 Jul; 10(3):327-43. PubMed ID: 26099670
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
